High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

British Journal of Cancer

Volumn 78, Issue 12, 1998, Pages 1634-1639

  Nielsen, O S ^a   Dombernowsky, P ^b   Mouridsen, H ^c   Crowther, D ^d   Verweij, J ^e   Buesa, J ^f   Steward, W ^g   Daugaard, S ^h   Van Glabbeke, M ⁱ   Kirkpatrick, A ⁱ   Tursz, T ^j  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c FINSEN LABORATORY   (Denmark)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h Rigshospitalet   (Denmark)

ⁱ EORTC DATA CENTER   (Belgium)

^j INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Doxorubicin; Epirubicin; High dose; Soft tissue sarcomas

Indexed keywords

DOXORUBICIN; EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 7844252263     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.735     Document Type: Article

References (21)

1. Blackledge G, van Oosterom AT, Mouridsen HT, Bramwell V, Santoro A, Verweij J, Rouesse J, Somers R, Wagener T, Buesa J, Steward WP, Spooner D, van Unnik J, Thomas D and Sylvester R (1990) Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease: an EORTC soft tissue and bone sarcoma group study. Eur J Cancer Clin Oncol 26: 139-141
2. Borden EC, Amato DA and Rosenbaum CH (1987) Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5: 840-850
3. Bramwell VHC, Mouridsen HT, Mulder JH, Somers R, van Oosterom A, Santoro A, Thomas D, Sylvester R and Markham D (1983) Carminomycin vs. adriamycin in advanced soft tissue sarcomas: an EORTC randomized phase II study. Eur J Cancer Clin Oncol 19: 1097-1104
4. Bull FE, von Hoff DD, Balcerak SP, Stephens RL and Panettiere FJ (1985) Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. Cancer Treat Rep 69: 231-233
5. Chevalier B, Monteuquet PH, Fachini T, Nguyen Bui B, Kerbrat P, Baslit P and Vo Van ML (1990) Phase II study of epirubicin in advanced soft tissue sarcomas. Bull Cancer 77: 991-995
6. Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S and Parkinson DR (1993) Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-1275
7. Gottlieb JA, Baker LJ, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SA, Bodey GP, Rodriguez, Blumenschein GR, Saiki JH, Coltman C, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Baicerzak S and Moon TE (1975) Adriamycin (NSC 123127) used alone and in combination for soft tissue and bone sarcomas. Cancer Chemother Rep 6: 271-282
8. Hryniuk W and Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288
9. Jelic S, Vuletic L, Milanovic N, Tomasevic Z and Kovcin V (1990) High-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Tumori 76: 467-471
10. Kaplan E and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
11. Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramweel V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D and Sylvester R (1987) Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol 23: 1477-1483
12. O'Bryan RM, Luce JK and Talley RW (1973) Phase II evaluation of adriamycin in human neoplasm. Cancer 32: 1-8
13. Reto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard V, Mantel N, McPherson K, Peto J and Smith PG (1977) Design and analysis of clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1-39
14. Pinedo HM, Bramwell VHC, Mouridsen H, Somers R, Vendrik CP, Santoro A, Buesa J, Wagener T, van Oosterom A and van Unnik JA (1984) CYVADIC in advanced soft tissue sarcoma: a randomized study comparing two schedules. Cancer 53: 1825-1832
15. Plosker GL and Faulds D (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45: 788-856
16. Robinson MH (1994) The management of adult soft tissue sarcomas. Clin Oncol 6: 183-192
17. Santoro A, Tursz T, Mouridsen HT, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, van Glabbeke M and van Oosterom A (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the EORTC soil tissue and bone sarcoma group. J Clin Oncol 13: 1537-1545
18. Suit HD (1995) Tumours of the connective and supporting tissues. Radiother Oncol 34: 93-104
19. Suit HD, van Groeningen CJ, Mankin HJ and Rosenberg AE (1995) Sarcoma of the soft tissues. In Oxford Textbook of Oncology. Peckham M, Pinedo H and Veronesi U (eds), pp. 1917-1939. Oxford University Press: Oxford
20. Vantongelen K, Rotmensz N and Van der Schueren E (1989) Quality control of validity of data collected in clinical trials. Eur J Cancer Clin Oncol 8: 1241-1247
21. Verweij J, Mouridsen HT, Nielsen OS, Woll P, Somers R, van Oosterom A, van Glabbeke M and Tursz T (1995) The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of views. Crit Rev Oncol/Hematol 20: 193-201